MannKind Corp (MNKD)

1.93
0.06 2.80
NASDAQ : Health Care
Prev Close 1.98
Open 1.99
Day Low/High 1.93 / 2.00
52 Wk Low/High 0.64 / 5.37
Volume 673.00K
Avg Volume 2.39M
Exchange NASDAQ
Shares Outstanding 104.68M
Market Cap 211.46M
EPS 1.40
P/E Ratio 1.38
Div & Yield N.A. (N.A)

Latest News

MannKind Corporation Reports 2017 Second Quarter Financial Results

MannKind Corporation Reports 2017 Second Quarter Financial Results

Conference Call to Begin Today at 5:00 PM ET

MannKind And One Drop Partner To Launch The A-ONE Clinical Trial

MannKind And One Drop Partner To Launch The A-ONE Clinical Trial

Study will utilize Afrezza® inhaled insulin and the One Drop digital diabetes care platform

MannKind And One Drop Partner To Launch The A-One Clinical Trial

MannKind And One Drop Partner To Launch The A-One Clinical Trial

Study will utilize Afrezza® inhaled insulin and the One Drop digital diabetes care platform

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Former hedge funder and biotech CEO Martin Shkreli finds himself in limbo as a criminal jury now decides if allegations of fraud will put him in orange coveralls.

MannKind Provides Update On Senior Management

Michael Castagna appointed Chief Executive Officer and Member of MannKind Board of Directors

MannKind Corporation Reports 2017 First Quarter Financial Results

Conference Call to Begin Today at 5:00 PM ET

Mannkind in Free Fall After Changes to Insulin Product, Sales Force

Mannkind in Free Fall After Changes to Insulin Product, Sales Force

Shares of insulin maker Mannkind plummeted on news of a proposed stock split, staffing changes and a new iteration of its insulin.

Mannkind Stock Drops Following Changes to Its Insulin Product

Mannkind Stock Drops Following Changes to Its Insulin Product

Mannkind stock is suffering, and the company appears to be in trouble.

Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open

Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open

Other movers included Mannkind, Perrigo and Bristol-Myers Squibb.

Insulin Drug Offers Hope for MannKind

Insulin Drug Offers Hope for MannKind

The stock has taken a beating, but users of Afrezza are loyal to the drug.

TheStreet Quant Rating: E+ (Sell)